242 related articles for article (PubMed ID: 22527101)
1. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
Hertz DL; Motsinger-Reif AA; Drobish A; Winham SJ; McLeod HL; Carey LA; Dees EC
Breast Cancer Res Treat; 2012 Jul; 134(1):401-10. PubMed ID: 22527101
[TBL] [Abstract][Full Text] [Related]
2. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
Bergmann TK; Gréen H; Brasch-Andersen C; Mirza MR; Herrstedt J; Hølund B; du Bois A; Damkier P; Vach W; Brosen K; Peterson C
Eur J Clin Pharmacol; 2011 Jul; 67(7):693-700. PubMed ID: 21327421
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
[TBL] [Abstract][Full Text] [Related]
4. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
[TBL] [Abstract][Full Text] [Related]
5. Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
Lee MY; Apellániz-Ruiz M; Johansson I; Vikingsson S; Bergmann TK; Brøsen K; Green H; Rodríguez-Antona C; Ingelman-Sundberg M
Pharmacogenomics; 2015; 16(9):929-37. PubMed ID: 26115084
[TBL] [Abstract][Full Text] [Related]
6. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
Fransson MN; Gréen H; Litton JE; Friberg LE
Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
[TBL] [Abstract][Full Text] [Related]
7. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.
Chang H; Rha SY; Jeung HC; Im CK; Ahn JB; Kwon WS; Yoo NC; Roh JK; Chung HC
Ann Oncol; 2009 Feb; 20(2):272-7. PubMed ID: 18836089
[TBL] [Abstract][Full Text] [Related]
8. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.
Hertz DL; Roy S; Motsinger-Reif AA; Drobish A; Clark LS; McLeod HL; Carey LA; Dees EC
Ann Oncol; 2013 Jun; 24(6):1472-8. PubMed ID: 23413280
[TBL] [Abstract][Full Text] [Related]
9. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
Rizzo R; Spaggiari F; Indelli M; Lelli G; Baricordi OR; Rimessi P; Ferlini A
Breast Cancer Res Treat; 2010 Nov; 124(2):593-8. PubMed ID: 20632082
[TBL] [Abstract][Full Text] [Related]
10. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
Lam SW; Frederiks CN; van der Straaten T; Honkoop AH; Guchelaar HJ; Boven E
Br J Cancer; 2016 Nov; 115(11):1335-1342. PubMed ID: 27736846
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Tanabe Y; Shimizu C; Hamada A; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yamamoto H; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1179-1186. PubMed ID: 28447211
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
Leskelä S; Jara C; Leandro-García LJ; Martínez A; García-Donas J; Hernando S; Hurtado A; Vicario JC; Montero-Conde C; Landa I; López-Jiménez E; Cascón A; Milne RL; Robledo M; Rodríguez-Antona C
Pharmacogenomics J; 2011 Apr; 11(2):121-9. PubMed ID: 20212519
[TBL] [Abstract][Full Text] [Related]
13. CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.
Jernström H; Bågeman E; Rose C; Jönsson PE; Ingvar C
Br J Cancer; 2009 Dec; 101(11):1817-23. PubMed ID: 19935798
[TBL] [Abstract][Full Text] [Related]
14. Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.
Hertz DL; Roy S; Jack J; Motsinger-Reif AA; Drobish A; Clark LS; Carey LA; Dees EC; McLeod HL
Breast Cancer Res Treat; 2014 May; 145(1):245-54. PubMed ID: 24706167
[TBL] [Abstract][Full Text] [Related]
15. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.
Bergmann TK; Brasch-Andersen C; Gréen H; Mirza MR; Skougaard K; Wihl J; Keldsen N; Damkier P; Peterson C; Vach W; Brøsen K
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):199-204. PubMed ID: 21955855
[TBL] [Abstract][Full Text] [Related]
16.
Abdelfattah NM; Solayman MH; Elnahass Y; Sabri NA
Genet Test Mol Biomarkers; 2021 Jul; 25(7):471-477. PubMed ID: 34280009
[No Abstract] [Full Text] [Related]
17. Influence of (C1236T and C3435T) Polymorphisms of ABCB1 Gene on Chemotherapy Treatment Outcome and Toxicity in Breast Cancer Patients.
Gudur RA; Bhosale SJ; Gudur AK; Kale SR; More AL; Datkhile KD
Asian Pac J Cancer Prev; 2024 May; 25(5):1567-1577. PubMed ID: 38809628
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.
Alcazar-González GA; Calderón-Garcidueñas AL; Garza-Rodríguez ML; Rubio-Hernández G; Escorza-Treviño S; Olano-Martin E; Cerda-Flores RM; Castruita-Avila AL; González-Guerrero JF; le Brun S; Simon-Buela L; Barrera-Saldaña HA
Pharmacogenomics; 2013 Oct; 14(13):1583-92. PubMed ID: 24088129
[TBL] [Abstract][Full Text] [Related]
19. Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.
Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):493-8. PubMed ID: 25424246
[TBL] [Abstract][Full Text] [Related]
20. Single agent weekly paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a feasibility study.
Gupta S; Bharath R; Shet T; Desai SB; Patil VM; Bakshi A; Parmar V; Badwe RA
Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):604-9. PubMed ID: 22014455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
